scPharmaceuticals

75 Arlington Street
Boston
Massachussetts
02116
United States

Website: http://scpharma.com/

Show jobs for this employer

47 articles with scPharmaceuticals

  • FDA Action Alert: Urovant, Athenex, scPharmaceuticals and Vertex

    The U.S. FDA is plenty busy with COVID-19 vaccine Emergency Use Authorizations this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. Here’s a look.

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced it received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) on December 3, 2020 regarding the Company’s New Drug Application (“NDA”) for FUROSCIX®.

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 3 at 11:20am EST. A live

  • Commercialization preparedness activities continuing ahead of December 30 PDUFA date for FUROSCIX® (furosemide injection) for subcutaneous administration

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual London Healthcare Conference

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today provided a business update on FUROSCIX ® , its investigational proprietary formulation of furosemide for subcutaneous administration. “As we look forward to our upcoming December 30, 2020 PDUFA date

  • scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX ® (furosemide) for subcutaneous administration FUROSCIX ® is currently under development for the treatment of congestion due to fluid overload in adult patients with worsening heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization Call on Tuesday, September 29, 2020 at 11am Eastern Time BURLINGTON, Mass.--( BUSINESS WIRE )-- scPha

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that management will participate in two upcoming investor conferences. John Tucker, Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright

  • scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced financial results for the second quarter ended June 30, 2020 and provided a business update.

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the U.S. Food and Drug A

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Sara Bonstein to its Board of Directors. Ms. Bonstein fills the vacancy created from Dorothy Coleman’s resignation from the Board of Directors. Ms. Co

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) se

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a new presentation time for BMO’s Virtual 2020 Prescriptions for Success Healthcare Conference, which is being held on Tuesday, June 23. John Tucker, chief executive off

  • scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, chief executive officer, will present at the following investor conferences in June: Jefferies Virtual Healthcare Conference Presentation: Thurs

  • scPharmaceuticals Inc. announced the pricing of an underwritten public offering of 5,780,347 shares of its common stock at a public offering price of $8.65 per share, before deducting underwriting discounts and commissions and other offering expenses, for gross proceeds of approximately $50.0 million.

  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has commenced an underwritten public offering of shares of its common stock.

  • Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020 Strong balance sheet with over $75M in cash Projected annual loss for 2020 narrows to $36-40M BURLINGTON, Mass.--( BUSINESS WIRE )-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs,

  • scPharmaceuticals Inc. announced financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.

  • Feb. 26, 2020 13:00 UTC scPharmaceuticals Inc. to Present at the Cowen and Company’s 40 th Annual Health Care Conference BURLINGTON, Mass.--( BUSINESS WIRE )-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced that John Tucker, president and chief executive officer, will present at

  • Feb. 20, 2020 13:00 UTC scPharmaceuticals Inc. to Present at the 9 th Annual SVB Leerink Global Healthcare Conference BURLINGTON, Mass.--( BUSINESS WIRE )-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced that John Tucker, president and chief executive officer, will present at the